Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/2003
08/07/2003US20030149003 Functionalized stilbene derivatives as improved vascular targeting agents
08/07/2003US20030149001 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
08/07/2003US20030148985 Methods and reagents for the inhibition of hepatitis B virus replication
08/07/2003US20030148976 For therapy of cancer, infectious disease, and allergic disorders
08/07/2003US20030148949 Administering a trefoil peptide or biologically active fragment thereof to a skin lesion or region of the skin where a lesion is to be prevented; wound healing agents which can speed healing, reduce pain and delay/prevent lesions
08/07/2003US20030148947 MIP as a research tool for identification, characterization and purification of molecules involved in cellular transport and osmotic regulation; agonists/antagonists; vision defects; anitinflammatory agents; nervous system and kidney disorders
08/07/2003US20030148946 Method and compositions for preventing hormone induced adverse effects
08/07/2003US20030148939 Compositions and methods related to claudin-7
08/07/2003US20030148936 Bioactive peptides
08/07/2003US20030148934 Human growth factor modulators (GFMO) polynucleotides which identify and encode GFMO; amino acid sequences, expression vectors, host cells, antibodies, agonists, and antagonists; anticarcinogenic agents; fibrotic disorders
08/07/2003US20030148926 Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
08/07/2003US20030148920 For inhibiting tumor-induced angiogenesis; antiischemic agents
08/07/2003US20030148517 Preparation and compositions for antrodia camphorata mycelium biologically active material
08/07/2003US20030148516 Medium containing flt3 ligand for culturing hematophoietic cells
08/07/2003US20030148513 Preparing culture of pluripotent brain tissue for nervous tissue regeneration, tissue engineering and treating nervous system disorders
08/07/2003US20030148420 Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase
08/07/2003US20030148409 Genetically engineered monoclonal di/tri/tetra antibodies preferential tumor associated antigens for use in diagnosis and treatment of tumors
08/07/2003US20030148408 Compositions and methods for the diagnosis and treatment of tumor
08/07/2003US20030148394 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058, or 6351 molecules
08/07/2003US20030148382 PanCAM nucleic acids and polypeptides
08/07/2003US20030148331 Novel human hepatoma associated protein and the polynucleotide encoding said polypeptide
08/07/2003US20030148327 Nucleic acid of given sequence; oligonucleotides and oligomers for detecting the cytosine methylation of genes; tumors and cancer
08/07/2003US20030148326 Diagnosis of diseases associated with dna transcription
08/07/2003US20030148285 Source of Immunodominant MHC-associated Peptides (SIMP); antibodies, probes, and cells, to characterize SIMP, modulate its cellular levels, diagnose and treat cancers and modulate immune response
08/07/2003US20030148274 Identification of neural defects associated with the nucleosomal assembly protein 112 gene
08/07/2003US20030148271 Given amino acid sequence; expression vectors, host cells; diagnosis, prevention and treatment of diseases associated with expression of the kallikrein
08/07/2003US20030148264 PDZ (PSD-95/Discs large/ZO-I) domains, (PSD-95 = post-synaptic density protein-95); PDZ proteins involved in assembling ion channels and other transmembrane receptors, at specialized subcellular sites such as tight junctions
08/07/2003US20030148099 Microcapsules having high carotenoid content
08/07/2003US20030147945 Vehicles stably associated with non-antagonistic combinations of >/= 2 synergistic agents
08/07/2003US20030147937 Di-myo-inositol phosphate, cyclic 2,3 diphosphoglycerate, 1,1-di- glycerol phosphate, mannosylglycerate, mannosyl glyceramide and/or di-mannosyl-di-inositol phosphate; protecting organisms, organs, tissues, cells from oxidation
08/07/2003US20030147915 Antibodies specific for seroreactive regions on HPV 16 proteins E1 and E2
08/07/2003US20030147905 Administering an oligopeptide for immunotherapy
08/07/2003US20030147896 A mixture of seven herbs, extract or chemically synthesized as anticancer agent: Tinospora cordifolia, Chlorphyton borivilianum, Curcuma longa, Asparagus racemosus, Hygrophila auriculata, Achyranthus aspera and Elephantopus scaber
08/07/2003US20030147893 Novel human transmembrane 4 superfamily protein
08/07/2003US20030147887 B-cell lymphoma specific antigen for use in diagnosis and treatment of B-cell malignancies
08/07/2003US20030147884 Administering a breast cancer patient (caused by human ErbB2 oncogene which codes a transmebrane glycoprotein receptor related to epidermal growth factor receptor, is overexpressed) an anti ErbB2 antibody and a drug
08/07/2003US20030147871 An immunotherapy by administering two engineered mammalian cells that each expresses IL-12 and IL-18 interleukins; synergistic response; antitumor treatment
08/07/2003US20030147866 Novel BGP compounds for therapy and diagnosis and methods for using same
08/07/2003US20030147862 Administering a colony stimulating factor and/or a nucleic acids encoding the factor; treating a vascular tumor
08/07/2003US20030147850 Composition and methods for potentiating therapeutic effects of interferons
08/07/2003US20030147845 O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato) pyrrolidin-1-yl]diazen-1-ium-1,2-diolates
08/07/2003US20030147844 A water soluble polymer conjugated drug containing mercaptan group; controlled pharmacokinetics and improved bioavailability, relative to unmodified bioactive materials
08/07/2003US20030147809 Antitumor agents
08/07/2003CA2714295A1 Desaturase genes, enzymes encoded thereby, and uses thereof
08/07/2003CA2475003A1 Double-stranded oligonucleotides
08/07/2003CA2474910A1 Oligonucleotide compositions with enhanced efficiency
08/07/2003CA2474908A1 Aggrecanase molecules
08/07/2003CA2474852A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis
08/07/2003CA2474794A1 Method of providing prophylaxis for tuberculosis in hiv positive individuals
08/07/2003CA2474777A1 Adenoviral vectors for modulating the cellular activities associated with pods
08/07/2003CA2474702A1 Heterocyclic arylsulfonamidobenzylic compounds
08/07/2003CA2474649A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
08/07/2003CA2474616A1 Human monoclonal antibodies to prostate specific membrane antigen (psma)
08/07/2003CA2474593A1 N, n'-dimethylated n-confused porphyrins
08/07/2003CA2474571A1 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells
08/07/2003CA2474497A1 Compositions and methods related to tim-3, a th1-specific cell surface molecule
08/07/2003CA2474434A1 Condensed heterocyclic compounds
08/07/2003CA2474433A1 Arylsulfonamidobenzylic compounds
08/07/2003CA2474414A1 Oligonucleotides comprising alternating segments and uses thereof
08/07/2003CA2473810A1 Fgfr agonists
08/07/2003CA2473249A1 New corticosteroids
08/07/2003CA2473169A1 Compounds that inhibit factor xa activity
08/07/2003CA2473164A1 Novel compounds that inhibit factor xa activity
08/07/2003CA2473162A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
08/07/2003CA2473128A1 Genetic polymorphisms in the preprotachykinin gene
08/07/2003CA2472296A1 Fap-activated anti-tumor compounds
08/07/2003CA2469738A1 Expression vectors encoding epitopes of target-associated antigens and methods for their design
08/07/2003CA2466228A1 Method for treating diseases with omega interferon
08/07/2003CA2453770A1 Compositions for preventing human cancer and method of preventing human cancer
08/07/2003CA2443023A1 8-heteroaryl xanthine adenosine a2b receptor antagonists
08/06/2003EP1333274A2 Up-converting reporters for biological and other assays using laser excitation techniques
08/06/2003EP1333094A2 Human telomerase catalytic subunit
08/06/2003EP1333033A1 FAP-activated anti-tumor compounds
08/06/2003EP1333025A1 Cyanopyrrolidine derivatives
08/06/2003EP1332762A1 Method of treating hyperprolactinemia and prolactinomas
08/06/2003EP1332761A1 Agonists of fibroblast growth factor receptors (FGFR)
08/06/2003EP1332755A1 Taxol liposome composition for treatment of cancer and preparation thereof
08/06/2003EP1332372A2 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression
08/06/2003EP1332368A2 Methods for detecting the efficacy of anticancer treatments
08/06/2003EP1332366A1 Methods for the treatment of cellular proliferative disorders
08/06/2003EP1332227A2 Nucleic acid ligands to the prostate specific membrane antigen
08/06/2003EP1332218A1 Differentiation-inducing substances
08/06/2003EP1332214A2 32144, a human fatty acid amide hydrolase and uses thereof
08/06/2003EP1332157A2 Prokineticin polypeptides, related compositions and methods
08/06/2003EP1332152A1 Peptide ligands for prostate specific antigen
08/06/2003EP1332151A1 Pyranoside derivatives
08/06/2003EP1332149A1 Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase
08/06/2003EP1332147A1 Thieno[2,3-c isoquinolines for use as inhibitors of parp
08/06/2003EP1332146A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
08/06/2003EP1332141A1 Quinazoline derivatives
08/06/2003EP1332139A2 Anticancer agents based on regulation of protein prenylation
08/06/2003EP1332137A2 Treatment of gastrointestinal stromal tumors
08/06/2003EP1332136A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
08/06/2003EP1332134A2 Inhibitors of prenyl-protein transferase
08/06/2003EP1332131A2 Acid derivatives useful as serine protease inhibitors
08/06/2003EP1332128A1 Benzamidine derivatives comprising a sulfate group serving as ltb4 antagonists
08/06/2003EP1331950A1 Methods and compositions for nucleic acid delivery
08/06/2003EP1331947A2 Use of citric acid as antimicrobial agent or enhancer or as anticancer agent
08/06/2003EP1331943A2 Nucleic acid molecules and polypeptides for immune modulation
08/06/2003EP1331940A1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
1 ... 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 ... 2211